BriaCell Therapeutics Cor... (BCTX)
NASDAQ: BCTX
· Real-Time Price · USD
3.98
-0.12 (-2.93%)
At close: May 02, 2025, 12:47 PM
-2.93% (1D)
| Bid | 3 |
| Market Cap | 22.72M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -11.59M |
| EPS (ttm) | -4.75 |
| PE Ratio (ttm) | -0.84 |
| Forward PE | -2.11 |
| Analyst | Buy |
| Ask | 5.06 |
| Volume | 307,264 |
| Avg. Volume (20D) | 1,486,945 |
| Open | 4.04 |
| Previous Close | 4.10 |
| Day's Range | 3.95 - 4.13 |
| 52-Week Range | 0.35 - 9.82 |
| Beta | 1.71 |
About BCTX
BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing immunotherapies for the treatment of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, a personalized immun...
Industry Biotechnology
Sector Healthcare
IPO Date Mar 14, 2012
Employees 16
Stock Exchange NASDAQ
Ticker Symbol BCTX
Website https://www.briacell.com
Analyst Forecast
According to 1 analyst ratings, the average rating for BCTX stock is "Buy." The 12-month stock price forecast is $32, which is an increase of 705.03% from the latest price.
Stock Forecasts1 week ago
-13.76%
BriaCell Therapeutics shares are trading lower aft...
Unlock content with
Pro Subscription
1 week ago
+11.05%
BriaCell Therapeutics shares are trading higher after the company announced it confirmed the sustained complete resolution of the lung metastasis two months after initial treatment in the ongoing Phase 1/2 Bria-OTS study.
